ORMP
Oramed Pharmaceuticals Inc
$
2.120
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.148
Open
2.120
VWAP
2.12
Vol
17.73K
Mkt Cap
86.59M
Low
2.090
Amount
37.54K
EV/EBITDA(TTM)
--
Total Shares
40.63M
EV
-44.97M
EV/OCF(TTM)
--
P/S(TTM)
43.56
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Show More
Valuation Metrics
The current forward P/E ratio for Oramed Pharmaceuticals Inc (ORMP.O) is -30.29, compared to its 5-year average forward P/E of -10.89. For a more detailed relative valuation and DCF analysis to assess Oramed Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-10.89
Current PE
-30.29
Overvalued PE
-0.73
Undervalued PE
-21.05
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.19
Undervalued EV/EBITDA
-5.12
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
81.62
Current PS
0.00
Overvalued PS
151.15
Undervalued PS
12.09
Financials
Annual
Quarterly
FY2025Q1
2.00M
Total Revenue
FY2025Q1
YoY :
+51.92%
-4.50M
Operating Profit
FY2025Q1
YoY :
-598.17%
-7.64M
Net Income after Tax
FY2025Q1
YoY :
-575.00%
-0.19
EPS - Diluted
FY2025Q1
YoY :
+138.29%
-3.52M
Free Cash Flow
FY2025Q1
0.65
Gross Profit Margin - %
FY2025Q1
YoY :
-43.78%
-523.70
FCF Margin - %
FY2025Q1
-382.10
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
65.0K
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ORMP News & Events
Events Timeline
2025-04-28 (ET)
2025-04-28
09:05:26
Alpha Tau enters strategic marketing alliance with Oramed
2025-04-28
09:04:22
Oramed announces $36.9M investment and collaboration with Alpha Tau
2025-02-11 (ET)
2025-02-11
08:19:45
Oramed enters JV for insulin development and commercialization
Sign Up For More Events
Sign Up For More Events
News
8.5
04-28NewsfilterOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
8.5
04-28NewsfilterAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
8.5
04-28SeekingAlphaOramed Pharmaceuticals invests $36.9 M in Alpha Tau Medical
Sign Up For More News
People Also Watch
VOR
Vor Biopharma Inc
2.210
USD
-7.14%
CTOR
Citius Oncology Inc
1.530
USD
-4.38%
ALXO
ALX Oncology Holdings Inc
0.507
USD
+3.05%
CODA
Coda Octopus Group Inc
7.980
USD
-3.39%
SHIM
Shimmick Corp
2.160
USD
-4.85%
ALOT
AstroNova Inc
11.220
USD
-0.53%
IROH
Iron Horse Acquisitions Corp
10.700
USD
+0.94%
FSHP
Flag Ship Acquisition Corp
10.465
USD
-0.05%
PAVS
Paranovus Entertainment Technology Ltd
0.840
USD
-3.45%
HSPO
Horizon Space Acquisition I Corp
12.050
USD
-0.90%
FAQ
What is Oramed Pharmaceuticals Inc (ORMP) stock price today?
The current price of ORMP is 2.12 USD — it has increased 0 % in the last trading day.
What is Oramed Pharmaceuticals Inc (ORMP)'s business?
What is the price predicton of ORMP Stock?
What is Oramed Pharmaceuticals Inc (ORMP)'s revenue for the last quarter?
What is Oramed Pharmaceuticals Inc (ORMP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Oramed Pharmaceuticals Inc (ORMP)'s fundamentals?
How many employees does Oramed Pharmaceuticals Inc (ORMP). have?